Department of Orthopedics and Traumatology, Department of Acupuncture and Moxibustion, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2205-2217. doi: 10.26355/eurrev_202003_20486.
Many findings have demonstrated long noncoding RNAs (lncRNAs) as crucial regulatory molecules in the progression of osteosarcoma. The aim of this study was to explore the roles and mechanisms of LncRNA LINC00689 (LINC00689) in osteosarcoma.
Differential levels of LINC00689 and miR-655 in osteosarcoma samples and cell lines were analyzed by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The associations between LINC00689 expression and prognostic significance of osteosarcoma patients were analyzed using a series of statistical assays. Loss-of-function and gain-of-function assays were performed to investigate the role of LINC00689 in proliferation and metastasis in vitro. Bioinformatic assays, Luciferase report assays, and rescue assays were applied to illustrate the ceRNA mechanism network of LINC00689/miR-655/SOX18.
We found that LINC00689 expression was distinctly upregulated in osteosarcoma specimens and cell lines. MiR-655 displayed a trend of remarkably decreased expression in osteosarcoma tissues. In addition, we showed that LINC00689 could specifically interact with the promoter of SP1 and activate LINC00689 transcription. Further clinical studies indicated that higher levels of LINC00689 were associated with advanced clinical stage, positively distant metastasis, and unfavorable clinical outcome. Functional studies revealed that the knockdown of LINC00689 suppressed the proliferation, migration, and invasion of osteosarcoma cells, and promoted apoptosis. Final mechanistic investigations confirmed that upregulation of LINC00689 competitively bound to miR-655 that prevented SOX18 from miRNA-mediated degradation, thus facilitating osteosarcoma progression.
All our findings suggested that SP1-induced upregulation of LINC00689 promoted osteosarcoma progression by regulating miR-655/ SOX18 axis, which provided a novel insight for osteosarcoma tumorigenesis.
许多研究结果表明,长链非编码 RNA(lncRNA)在骨肉瘤的进展中是重要的调控分子。本研究旨在探讨 LncRNA LINC00689(LINC00689)在骨肉瘤中的作用和机制。
通过实时定量聚合酶链反应(qRT-PCR)分析骨肉瘤样本和细胞系中 LINC00689 和 miR-655 的差异水平。通过一系列统计分析评估 LINC00689 表达与骨肉瘤患者预后的相关性。通过体外失能和增益功能测定来研究 LINC00689 在增殖和转移中的作用。应用生物信息学测定、荧光素酶报告测定和挽救测定来阐明 LINC00689/miR-655/SOX18 的 ceRNA 机制网络。
我们发现 LINC00689 在骨肉瘤标本和细胞系中表达明显上调。miR-655 在骨肉瘤组织中表达呈明显下降趋势。此外,我们表明 LINC00689 可以与 SP1 的启动子特异性相互作用并激活 LINC00689 的转录。进一步的临床研究表明,较高水平的 LINC00689 与晚期临床分期、远处转移阳性和不良临床结局相关。功能研究表明,LINC00689 的敲低抑制了骨肉瘤细胞的增殖、迁移和侵袭,并促进了细胞凋亡。最终的机制研究证实,LINC00689 的上调可竞争性结合 miR-655,防止 SOX18 被 miRNA 介导的降解,从而促进骨肉瘤的进展。
我们的研究结果表明,SP1 诱导的 LINC00689 上调通过调节 miR-655/SOX18 轴促进骨肉瘤的进展,为骨肉瘤的发生提供了新的认识。